DMARDs (biologic)

Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
Peter Nash, Frank Behrens, Ana-Maria Orbai, Suchitrita S Rathmann, David H Adams, Olivier Benichou, Atul Deodhar

RMD Open Sep 2018, 4 (2) e000692; DOI: 10.1136/rmdopen-2018-000692
Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population
Boulos Haraoui, Algis Jovaisas, William G Bensen, Rafat Faraawi, John Kelsall, Sanjay Dixit, Jude Rodrigues, Maqbool Sheriff, Emmanouil Rampakakis, John S Sampalis, Allen J Lehman, Susan Otawa, Francois Nantel, May Shawi

RMD Open Apr 2015, 1 (1) e000078; DOI: 10.1136/rmdopen-2015-000078
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
Vibeke Strand, Eduardo Mysler, Robert J Moots, Gene V Wallenstein, Ryan DeMasi, David Gruben, Koshika Soma, Noriko Iikuni, Josef S Smolen, Roy Fleischmann

RMD Open Oct 2019, 5 (2) e001040; DOI: 10.1136/rmdopen-2019-001040
Large granular lymphocyte expansions in primary Sjögren’s syndrome: characteristics and outcomes
Alistair Baber, Gaetane Nocturne, Roman Krzysiek, Julien Henry, Rakiba Belkhir, Xavier Mariette, Raphaele Seror

RMD Open Oct 2019, 5 (2) e001044; DOI: 10.1136/rmdopen-2019-001044
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
Gerd R Burmester, Vibeke Strand, Andrea Rubbert-Roth, Howard Amital, Tatiana Raskina, Antonio Gómez-Centeno, Claudia Pena-Rossi, Leon Gervitz, Karthinathan Thangavelu, Gregory St John, Susan Boklage, Mark C Genovese

RMD Open Oct 2019, 5 (2) e001017; DOI: 10.1136/rmdopen-2019-001017
Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapies
AnnaCarin Horne, Bénédicte Delcoigne, Karin Palmblad, Johan Askling

RMD Open Nov 2019, 5 (2) e001055; DOI: 10.1136/rmdopen-2019-001055
Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible
Olafur Palsson, Thorvardur Jon Love, Anna Ingibjorg Gunnarsdottir, Petur Sigurdur Gunnarsson, Eydis Erla Runarsdottir, Niels Steen Krogh, Bjorn Gudbjornsson

RMD Open Jul 2019, 5 (2) e000984; DOI: 10.1136/rmdopen-2019-000984
Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift
Katerina Chatzidionysiou, Petros P Sfikakis

RMD Open Jul 2019, 5 (2) e000993; DOI: 10.1136/rmdopen-2019-000993
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
Xenofon Baraliakos, Juergen Braun, Atul Deodhar, Denis Poddubnyy, Alan Kivitz, Hasan Tahir, Filip Van den Bosch, Evie-Maria Delicha, Zsolt Talloczy, Anke Fierlinger

RMD Open Sep 2019, 5 (2) e001005; DOI: 10.1136/rmdopen-2019-001005
Secukinumab does not impair the immunogenic response to the influenza vaccine in patients
Patricia Richi, María Dolores Martín, Fernando de Ory, Rosa Gutiérrez-Larraya, Inmaculada Casas, Ana María Jiménez-Díaz, Fernando Cava, Santiago Muñoz-Fernandez

RMD Open Sep 2019, 5 (2) e001018; DOI: 10.1136/rmdopen-2019-001018

Main menu

DMARDs (biologic)

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

DMARDs (biologic)

Pages